@drlauraesserman.bsky.social
Judy Boughey's presidential address highlighted how important innovative trial design is for moving the field forward and talked about I SPY 2.2.- even though it is more complex, it is a wonderful way to treat patients
May 20, 2025 at 12:33 AM
Judy Boughey's presidential address highlighted how important innovative trial design is for moving the field forward and talked about I SPY 2.2.- even though it is more complex, it is a wonderful way to treat patients
Mandeep Kaur presenting on the disparity in the use of axillary dissection by race at ASBrS 2025
May 20, 2025 at 12:31 AM
Mandeep Kaur presenting on the disparity in the use of axillary dissection by race at ASBrS 2025
Julie van Hassel (award for best trainee) presented on the time to surgery after neoadjuvant chemo and impact on outcomes
(In the setting of excellent response, time is not important, but in setting of residual disease, > 9 weeks is associated with worse outcome)
(In the setting of excellent response, time is not important, but in setting of residual disease, > 9 weeks is associated with worse outcome)
May 20, 2025 at 12:30 AM
Julie van Hassel (award for best trainee) presented on the time to surgery after neoadjuvant chemo and impact on outcomes
(In the setting of excellent response, time is not important, but in setting of residual disease, > 9 weeks is associated with worse outcome)
(In the setting of excellent response, time is not important, but in setting of residual disease, > 9 weeks is associated with worse outcome)
Rita Mukhtar and down staging of the axilla in lobular vs. ductal on I SPY at ASBrS 2025
May 20, 2025 at 12:27 AM
Rita Mukhtar and down staging of the axilla in lobular vs. ductal on I SPY at ASBrS 2025
RISE UP taught us that BZA is perhaps one of the best agents to target endocrine positive tumors. We are really excited to be participating in a trial that is testing to see if BZA combined with a small amount of estrogen can be risk-reducing and at the same time relieve women of hot flashes.
December 17, 2024 at 1:30 AM
RISE UP taught us that BZA is perhaps one of the best agents to target endocrine positive tumors. We are really excited to be participating in a trial that is testing to see if BZA combined with a small amount of estrogen can be risk-reducing and at the same time relieve women of hot flashes.